Nick Duncan is principal pharmacist in haematology and oncology at University Hospitals Birmingham NHS Foundation Trust.
Although multiple myeloma is currently regarded as being incurable in the majority of patients, the outlook for patients diagnosed with the condition has improved markedly over the last 40 years, with survival rates quadrupling. Significant advances in both treatment and supportive therapies have contributed to these improved outcomes and are discussed in this article.
Lymphomas: current and future treatment optionsSubscription
The management of lymphomas involves a range of different chemotherapy schedules, with novel medicines emerging and offering better treatment options.
Lymphomas are some of the most common cancers in the UK, with a wide variation in disease progression and prognosis between subtypes.
Multiple myeloma: managementSubscription